Advanced search
Start date
Betweenand

Evaluation of antineoplastic effects of Zebularina on medulloblastoma cell lines

Grant number: 11/22440-7
Support type:Scholarships in Brazil - Doctorate
Effective date (Start): April 01, 2012
Effective date (End): March 31, 2016
Field of knowledge:Health Sciences - Medicine
Principal Investigator:Luiz Gonzaga Tone
Grantee:Augusto Faria Andrade
Home Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
Associated scholarship(s):14/06947-2 - Identification of new targets involved in chemoresistance, BE.EP.DR

Abstract

Medulloblastoma is a central nervous system cancer, which arises in the cerebellum. Its origin is embryonic and is considered highly invasive. It is the most common solid tumor in pediatric patients and its occurrence is more common in 5-7 year-old children. Corresponds to approximately 20% of all pediatric intracranial tumors. The most common treatment is surgery and chemotherapy, and radiotherapy is applied only to children over 3 years because of its side effects in the central nervous system. Several factors contribute to the development and progression of medulloblastoma. Among these, there are changes in signaling pathways such as Hedgehog, Notch and WNT, and epigenetic changes, such as acetylation and methylation of DNA. Such changes undertakes basic cell functions such as controlling apoptosis, cell proliferation, angiogenesis and metastasis. Despite the growing understanding of molecular mechanisms of MB, there are no therapies that significantly increase the survival of patients avoiding late side effects. Recently, epigenetic drugs as DNA methyltransferases inhibitors (iDNMTs) has shown promising results and anticancer effects both in hematologic and solid tumors. Zebularina is an iDNMTs that causes DNA demethylation. This agent has proved to be an antitumor drug with low toxicity, with adjuvant activity in anti-cancer chemotherapy in chemo-resistant tumors and is a great option for drug combination. Several studies have shown the anticancer effects of Zebularina in different types of cancer, however, there are no studies that report these effects in medulloblastoma cell lines.

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
ANDRADE, AUGUSTO FARIA; BORGES, KLEITON SILVA; SUAZO, VERIDIANA KIILL; GERON, LENISA; PEREIRA CORREA, CAROLINA ALVES; CASTRO-GAMERO, ANGEL MAURICIO; ROSAS DE VASCONCELOS, ELTON JOSE; DE OLIVEIRA, RICARDO SANTOS; NEDER, LUCIANO; YUNES, JOSE ANDRES; AGUIAR, SIMONE DOS SANTOS; SCRIDELI, CARLOS ALBERTO; TONE, LUIZ GONZAGA. The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma. INVESTIGATIONAL NEW DRUGS, v. 35, n. 1, p. 26-36, FEB 2017. Web of Science Citations: 10.
Academic Publications
(References retrieved automatically from State of São Paulo Research Institutions)
ANDRADE, Augusto Faria. Evaluation of antineoplastic effects of Zebularine in medulloblastoma. 2016. Doctoral Thesis - Universidade de São Paulo (USP). Faculdade de Medicina de Ribeirão Preto Ribeirão Preto.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.